Henrijette Richter

    Managing Partner

    Henrijette Richter is one of our managing partners and an active member of the Capital Funds team, our flagship fund dedicated to early-stage biotechs and medtechs.

    She joined Sofinnova in 2014, and her investments and board involvements include Mozart Therapeutics, Muna Therapeutics, Nitrase Therapeutics, Nodthera, Twentyeight-Seven Therapeutics, Asceneuron, Delinia (sold to Celgene), and iOmx Therapeutics.

    Henrijette was attracted by Sofinnova Partners’ focus on a positive, consensus-oriented environment and its philosophy of investing in people. “Everyone needs to agree. An individual’s  success is everyone's success,” she says. “And when there's a failure, it's everyone's failure — that fosters different conversations when you consider potential investments.”

    Prior to Sofinnova, Henrijette was part of the team that founded Novo Seeds in 2007, and as an Investment Director, she was instrumental in the creation, financing and building of companies such as Orphazyme (ORPHA.CO; ORPH), Avilex Pharma, EpiTherapeutics (sold to Gilead), and Lysogene (LYS, Euronext Paris).

    Henrijette holds a combined Ph.D. and Industrial Scientist degree in Molecular Biology from the University of Copenhagen and Novo Nordisk A/S. She did her postdoctoral fellowship at the MIT Center for Cancer Research in Massachusetts.

    “I joined Sofinnova Partners because first of all, they have a fantastic brand in Europe, but it's easy to see it is a very strong partnership. They're loyal to each other and everyone knows they treat entrepreneurs well.”

    Sectors

    Biopharmaceuticals & Medical Devices

    Related companies

    Join our mailing list

    Keep up to date with our latest news.

    Required
    Thanks for submitting the form. You are now subscribed to Sofinnova Partners news alerts.An error happened. Please try again later.